Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Bio‑Sincerity Pharma‑Tech Secures Greater China Priority Rights for Delim’s Semaglutide and Tirzepatide Portfolio

Fineline Cube Jan 23, 2026
Company Deals

TaiGen and Joincare Partner on TG‑4318 DPP1 Inhibitor for Bronchiectasis in Greater China

Fineline Cube Jan 23, 2026
Company Deals

China Isotope & Radiation Corporation Signs Commercial Deal for Pluvicto, China’s First PSMA Radioligand Therapy

Fineline Cube Jan 22, 2026
Company Deals

Matwings Technology Partners with Leading US Biotech on AIACCLBIO Platform for Biopharmaceutical Pipeline

Fineline Cube Jan 22, 2026
Company Deals

AmCellGene Licenses Mesenchymal Stem Cell Therapy for ACLF to Advanced Regeneration in First Chinese Stem Cell Outbound Deal

Fineline Cube Jan 22, 2026
Company Drug Policy / Regulatory

Merson’s Bemejing Wins First CNMR “Overseas Version” Drug Price Certificate

Fineline Cube Jan 21, 2026
Company Drug

Enhertu Wins China NMPA Approval for Second‑Line HER2‑Positive Gastric Cancer

Fineline Cube Jan 22, 2026
Company Drug

AstraZeneca’s Imfinzi Wins China Approval for Endometrial Cancer, Securing Seventh Indication

Fineline Cube Jan 22, 2026
Company Drug

Grand Pharmaceutical Group Ltd’s SIR-Spheres Set to Reach Wider Patient Base Through MediTrust Health Deal

Fineline Cube Jul 1, 2024

Grand Pharmaceutical Group Ltd (HKG: 0512), a leading pharmaceutical company based in China, has announced...

Company Drug

IASO Biotherapeutics’ RD118 CAR-T Therapy Receives Clinical Trial Approval for Multiple Myeloma

Fineline Cube Jul 1, 2024

IASO Biotherapeutics, a biopharmaceutical company based in China, has announced that it has received tacit...

Company Deals Drug

Yunnan Baiyao Group Secures Global Rights to Kyinno Biotechnology’s Antibody Drug KA-1641

Fineline Cube Jul 1, 2024

Yunnan Baiyao Group Co., Ltd (SHE: 000538), a traditional Chinese medicine (TCM) company based in...

Policy / Regulatory

China’s NHSA Releases 2024 National Reimbursement Drug List Adjustment Plan

Fineline Cube Jul 1, 2024

The National Healthcare Security Administration (NHSA) has published the National Reimbursement Drug List (2024) adjustment...

Company Drug

Henlius Pharmaceutical’s HLX15 Biosimilar Meets Phase I Clinical Endpoints

Fineline Cube Jul 1, 2024

Shanghai Henlius Biotech Co., Ltd (HKG: 2696) has announced the successful completion of a Phase...

Company Drug

CSPC Pharmaceutical’s Enronsubaimab Gets NMPA Nod for Recurrent Cervical Cancer

Fineline Cube Jul 1, 2024

CSPC Pharmaceutical Group Ltd (HKG: 1093), a leading pharmaceutical company based in China, has announced...

Company

Reckitt’s New Shanghai R&D Center to Boost Innovation in Health and Hygiene Products

Fineline Cube Jul 1, 2024

Reckitt (LON: RKT), a UK-based manufacturer of consumer health and hygiene products, is planning to...

Company Drug

Johnson & Johnson Achieves Positive Phase III Results for Nipocalimab in Generalized Myasthenia Gravis

Fineline Cube Jul 1, 2024

Johnson & Johnson (J&J, NYSE: JNJ), a leading US-based healthcare company, has announced positive results...

Company Deals

Hasten Biopharmaceutical Expands into Pan-Asia Regions with Celltrion Asset Acquisition

Fineline Cube Jul 1, 2024

Hasten Biopharmaceutical Co., Ltd, a China-based pharmaceutical company backed by CBC Group, has announced an...

Company Drug

Bio-Thera Solutions’ BAT2094 Wins NMPA Nod for Acute Coronary Syndrome Treatment

Fineline Cube Jul 1, 2024

Bio-Thera Solutions Ltd (SHA: 688177), a biopharmaceutical company based in China, has announced that it...

Company Drug

Takeda’s CEO Weber Eyes Further Partnerships with Chinese Biotechs Amid Innovation Surge

Fineline Cube Jul 1, 2024

Takeda Pharmaceutical Co., (TYO: 4502, NYSE: TAK), a leading Japanese pharmaceutical company, is actively seeking...

Company Drug

Luye Pharma’s Manufacturing Facility Passes FDA Inspection for Paliperidone Palmitate Product

Fineline Cube Jun 28, 2024

Luye Pharma Group (HKG: 2186), a Chinese pharmaceutical company, has announced that it has successfully...

Company Drug

Sirnaomics’ STP707 Shows Promising Results in Phase I Pancreatic Cancer Trial

Fineline Cube Jun 28, 2024

Sirnaomics Ltd (HKG: 2257), a biopharmaceutical company, has announced the successful completion of a Phase...

Company Deals

Shandong Junxiu Biotechnology Partners with Swiss Firm Geistlich to Boost Regenerative Medicine

Fineline Cube Jun 28, 2024

Shandong Junxiu Biotechnology Co., Ltd, a Chinese manufacturer of implantable regenerative medicine devices, has entered...

Company Drug

Genmab and AbbVie’s Epcoritamab Earns FDA Accelerated Approval for Follicular Lymphoma

Fineline Cube Jun 28, 2024

Genmab A/S (NASDAQ: GMAB), a Danish biotechnology company, and its co-development partner AbbVie (NYSE: ABBV),...

Company Deals

AbbVie Bolsters Inflammatory Disease Portfolio with Celsius Therapeutics Acquisition

Fineline Cube Jun 28, 2024

AbbVie (NYSE: ABBV), a major U.S. pharmaceutical company, has announced the acquisition of Celsius Therapeutics...

Company Drug

Novo Nordisk Plans Cautious Wegovy Launch in China to Preserve Global Supply

Fineline Cube Jun 28, 2024

Novo Nordisk (NYSE: NVO; CPH: NOVO-B), a leading healthcare company, has reportedly planned a cautious...

Company Deals

Novo Nordisk Moves to Acquire 2seventy bio’s Hemophilia A Program and Gene-Editing Technology

Fineline Cube Jun 28, 2024

Novo Nordisk (NYSE: NVO; CPH: NOVO-B), a leading Danish biopharmaceutical company, is transitioning from a...

Company Drug

Hybio Pharmaceutical Gets FDA Nod for Tirzepatide Raw Materials in DMF Filing

Fineline Cube Jun 28, 2024

Hybio Pharmaceutical Co., Ltd (SHE: 300199), a Chinese pharmaceutical company, has announced that it has...

Company Drug

Abbisko Therapeutics Presents Positive Phase II Results for HCC Treatment at ESMO-GI

Fineline Cube Jun 28, 2024

Abbisko Therapeutics Co., Ltd (HKG: 2256), a Shanghai-based biotech company, has announced the presentation of...

Posts pagination

1 … 285 286 287 … 613

Recent updates

  • Bio‑Sincerity Pharma‑Tech Secures Greater China Priority Rights for Delim’s Semaglutide and Tirzepatide Portfolio
  • TaiGen and Joincare Partner on TG‑4318 DPP1 Inhibitor for Bronchiectasis in Greater China
  • China Isotope & Radiation Corporation Signs Commercial Deal for Pluvicto, China’s First PSMA Radioligand Therapy
  • Matwings Technology Partners with Leading US Biotech on AIACCLBIO Platform for Biopharmaceutical Pipeline
  • AmCellGene Licenses Mesenchymal Stem Cell Therapy for ACLF to Advanced Regeneration in First Chinese Stem Cell Outbound Deal
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Bio‑Sincerity Pharma‑Tech Secures Greater China Priority Rights for Delim’s Semaglutide and Tirzepatide Portfolio

Company Deals

TaiGen and Joincare Partner on TG‑4318 DPP1 Inhibitor for Bronchiectasis in Greater China

Company Deals

China Isotope & Radiation Corporation Signs Commercial Deal for Pluvicto, China’s First PSMA Radioligand Therapy

Company Deals

Matwings Technology Partners with Leading US Biotech on AIACCLBIO Platform for Biopharmaceutical Pipeline

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.